Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluoxymesterone
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Fluoxymesterone is a synthetic androgen and anabolic steroid (AAS) used primarily to treat low testosterone levels in males (hypogonadism), delayed puberty in boys, and as palliative therapy for certain types of breast cancer in women. It acts as an agonist of the androgen receptor, mimicking the effects of endogenous testosterone. In men and boys, it replaces or supplements natural testosterone to promote normal development and function of male sexual organs and secondary sex characteristics. In women with hormone-responsive breast cancer, it suppresses estrogen production by antagonizing estrogen receptors or through negative feedback on the hypothalamic-pituitary-gonadal axis[1][2][3][5][6]. Fluoxymesterone is orally active due to its 17α-methyl group but carries a risk of hepatotoxicity[5]. It was first described in 1956 and introduced for medical use in 1957[5].
- Brand names
- HalotestinAndroxyUltandrenOra-Testryl
- Other names
- fluoxymesterone
02
Targets
HSD11B2 (11β-HSD2)AR (Adrenergic receptors)ER (Estrogen receptor)
Beyond the preview
Go deeper on fluoxymesterone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluoxymesterone.